Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis (MIRA-3)

The requested reference [9954b2d66af87d1d613f77a3e4fb7b433d3a3af9] no longer exists in our database. It has been replaced by the current reference: [80e8966b59ae29e096012faf2520f210fce22764]

Authors Ocuphire Pharma, Inc. -More
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2021
Links ClinicalTrials.gov
The objectives of this study are: * To evaluate the efficacy of Nyxol to expedite the reversal of pharmacologically-induced mydriasis across multiple mydriatic agents with an emphasis on phenylephrine * To evaluate the efficacy of Nyxol to return subjects to baseline accommodation after worsening (with cycloplegic agents tropicamide and Paremyd) * To evaluate the safety of Nyxol * To evaluate any additional benefits of the reversal of pharmacologically-induced mydriasis * To evaluate the systemic exposure of Nyxol on pharmacokinetic (PK) sampling
Epistemonikos ID: c012d8cd8cd884e1470acb29a6691ea57a5a76b1
First added on: May 09, 2024